[go: up one dir, main page]

WO2006048264A3 - Gene expression profiling in acute lymphoblastic leukemia (all), biphenotypic acute leukemia (bal), and acute myeloid leukemia (aml) m0 - Google Patents

Gene expression profiling in acute lymphoblastic leukemia (all), biphenotypic acute leukemia (bal), and acute myeloid leukemia (aml) m0 Download PDF

Info

Publication number
WO2006048264A3
WO2006048264A3 PCT/EP2005/011730 EP2005011730W WO2006048264A3 WO 2006048264 A3 WO2006048264 A3 WO 2006048264A3 EP 2005011730 W EP2005011730 W EP 2005011730W WO 2006048264 A3 WO2006048264 A3 WO 2006048264A3
Authority
WO
WIPO (PCT)
Prior art keywords
leukemia
acute
bal
gene expression
aml
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/011730
Other languages
French (fr)
Other versions
WO2006048264A2 (en
Inventor
Torsten Haferlach
Martin Dugas
Wolfgang Kern
Alexander Kohlmann
Susanne Schnittger
Claudia Schoch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH filed Critical F Hoffmann La Roche AG
Publication of WO2006048264A2 publication Critical patent/WO2006048264A2/en
Publication of WO2006048264A3 publication Critical patent/WO2006048264A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Genetics & Genomics (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Signal Processing (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to rapid and reliable approaches, based on gene expression, to detecting and classifying leukemia, in particular ALL, BAL and AMLMO. In addition to these classification methods, the invention also provides related kits and systems.
PCT/EP2005/011730 2004-11-04 2005-11-03 Gene expression profiling in acute lymphoblastic leukemia (all), biphenotypic acute leukemia (bal), and acute myeloid leukemia (aml) m0 Ceased WO2006048264A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62522104P 2004-11-04 2004-11-04
US60/625,221 2004-11-04

Publications (2)

Publication Number Publication Date
WO2006048264A2 WO2006048264A2 (en) 2006-05-11
WO2006048264A3 true WO2006048264A3 (en) 2006-09-21

Family

ID=35995492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/011730 Ceased WO2006048264A2 (en) 2004-11-04 2005-11-03 Gene expression profiling in acute lymphoblastic leukemia (all), biphenotypic acute leukemia (bal), and acute myeloid leukemia (aml) m0

Country Status (1)

Country Link
WO (1) WO2006048264A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007217366A1 (en) 2006-02-27 2007-08-30 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
WO2007137366A1 (en) * 2006-05-31 2007-12-06 Telethon Institute For Child Health Research Diagnostic and prognostic indicators of cancer
BR102015007391B1 (en) * 2015-04-01 2023-11-14 Instituto Hermes Pardini S.A. BIOMARKERS FOR CLASSIFICATION OF ACUTE LEUKEMIA
JP2016214239A (en) * 2015-05-15 2016-12-22 国立大学法人高知大学 Pancreatic cancer marker
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15 PGDH INHIBITORS WITH CORTICOSTEROIDS AND / OR TNF INHIBITORS AND USES THEREOF
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
BR112021009832A2 (en) 2018-11-21 2021-08-17 Case Western Reserve University compositions and methods of modulating short-chain dehydrogenase activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039443A2 (en) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
WO2004091511A2 (en) * 2003-04-10 2004-10-28 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039443A2 (en) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
WO2004091511A2 (en) * 2003-04-10 2004-10-28 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BERREBI A ET AL: "RAB-1: a new monoclonal antibody to leukemic hairy cells.", LEUKEMIA RESEARCH. 1986, vol. 10, no. 9, 1986, pages 1071 - 1078, XP002373273, ISSN: 0145-2126 *
CATOVSKY D ET AL: "Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7.", BLOOD. AUG 1981, vol. 58, no. 2, August 1981 (1981-08-01), pages 406 - 408, XP002373274, ISSN: 0006-4971 *
HAFERLACH T ET AL: "The Diagnosis of 14 Specific Subtypes of Leukemia Is Possible Based on Gene Expression Profiles: A Study on 263 Patients with AML, ALL, CML, or CLL", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 100, no. 11, 16 November 2002 (2002-11-16), pages 139A, XP002263227, ISSN: 0006-4971 *
KALEEM ZAHID ET AL: "Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.", ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. JAN 2003, vol. 127, no. 1, January 2003 (2003-01-01), pages 42 - 48, XP009063952, ISSN: 1543-2165 *
PARTANEN J ET AL: "PUTATIVE TYROSINE KINASES EXPRESSED IN K-562 HUMAN LEUKEMIA CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 87, November 1990 (1990-11-01), pages 8913 - 8917, XP001061403, ISSN: 0027-8424 *
SIMONEAUX DENISE K ET AL: "The receptor tyrosine kinase-related gene (ryk) demonstrates lineage and stage-specific expression in hematopoietic cells", JOURNAL OF IMMUNOLOGY, vol. 154, no. 3, 1995, pages 1157 - 1166, XP009063614, ISSN: 0022-1767 *
WANG X C ET AL: "H-RYK, an unusual receptor kinase: Isolation and analysis of expression in ovarian cancer", MOLECULAR MEDICINE, BLACKWELL SCIENCE, CAMBRIDGE, MA, US, vol. 2, no. 2, March 1996 (1996-03-01), pages 189 - 203, XP002955750, ISSN: 1076-1551 *

Also Published As

Publication number Publication date
WO2006048264A2 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
USD513774S1 (en) Hockey practice device
WO2008099241A3 (en) Weather information in a calendar
WO2007067316A3 (en) Ion sources, systems and methods
IN2012DN02302A (en)
WO2007138596A3 (en) User group identification
WO2004050839A3 (en) Fragmentation-based methods and systems for sequence variation detection and discovery
EP2312312A3 (en) Detection of conformationally altered proteins and prions
WO2006048262A3 (en) Classification of acute myeloid leukemia
WO2005118878A3 (en) Methods of screening for cell proliferation or neoplastic disorders
EP1651022A3 (en) support for a component
WO2007112279A3 (en) Resonators
WO2005065365A3 (en) Systems and methods for aesthetic improvement
TW200700644A (en) Composite fan and frame thereof
WO2007047408A3 (en) Promac signature application
WO2007073553A3 (en) Block copolymer particles
WO2006043047A3 (en) A spatial aggregator system for providing information
EP2253722A3 (en) Reagent and methods for detecting severe acute respiratory syndrome coronavirus
WO2006048264A3 (en) Gene expression profiling in acute lymphoblastic leukemia (all), biphenotypic acute leukemia (bal), and acute myeloid leukemia (aml) m0
EP1811023A4 (en) Gene expressed specifically in es cells and utilization of the same
WO2006084151A3 (en) Identify data sources for neural network
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
WO2006048263A3 (en) Gene expression profiling in acute promyelocytic leukemia
WO2004081537A3 (en) Methods of evaluating caloric restriction and identifying caloric restriction mimetics
EP1758065A3 (en) Method for forecasting a traffic condition in a road network and traffic management centre
WO2006048270A3 (en) Methods of detecting leukemia and its subtypes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05807889

Country of ref document: EP

Kind code of ref document: A2